Retatrutide Clinical Trial Near Me: How to Find and Enroll (2026)

What Is the TRIUMPH Program? (30-Second Orientation)

TRIUMPH is the name Eli Lilly gives to its Phase 3 retatrutide trial program. The rationale and design across its trials were described by Giblin and colleagues in Diabetes, Obesity and Metabolism in 2026 (PMID 41090431). Across the program, more than 5,800 participants have been enrolled in studies spanning obesity, sleep apnea, knee osteoarthritis, cardiovascular outcomes, and weight maintenance.

If you join a retatrutide study, you are joining one of these trials. You do not need to memorize the program to enroll, but knowing the major studies helps you read trial listings and recognize which one a site is running. For the full results-focused breakdown, see our TRIUMPH program overview.

Which Retatrutide Trials Are Still Recruiting?

Update, October 2, 2026: no TRIUMPH trial is recruiting any more. The retatrutide studies open on ClinicalTrials.gov are NCT07165028 (Phase 3, fatty liver disease) and NCT07467447 (Phase 2, obesity). This is the most time-sensitive part of any trial search, because recruitment status changes month to month. The snapshot below reflects ClinicalTrials.gov as of June 2026. Always confirm the live status yourself before contacting a site.

The main trials that enrolled the general obesity population, including TRIUMPH-1, have now completed enrollment. Lilly continues to run multiple retatrutide studies, and new trials can open at any time. The search process below will surface any study that is currently recruiting near you, including newer protocols not listed above.

Am I Eligible? Who TRIUMPH Trials Typically Enroll

Every trial sets its own inclusion and exclusion rules, but the general obesity arm gives a useful baseline for self-screening before you invest time in an application. The criteria below describe the typical profile based on TRIUMPH-1, verified against ClinicalTrials.gov in June 2026. They are not universal for all trials.

Who Is Typically Included

• Adults 18 years of age and older
• BMI of 30 kg/m² or higher (obesity), or BMI of 27 kg/m² or higher with at least one weight-related condition such as hypertension, dyslipidemia, sleep apnea, or cardiovascular disease
• No type 2 diabetes (TRIUMPH-1 specifically excluded diabetes; other trials differ)
• A history of unsuccessful weight loss through diet and lifestyle changes

Common Reasons People Are Excluded

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN syndrome type 2
• Prior pancreatitis
• A type 2 diabetes diagnosis (for the obesity-only arm)
• Body weight change greater than 5 kg in the 90 days before screening
• Use of any weight-loss medication within the prior 90 days
• Recent cardiovascular events, which are handled differently in the cardiovascular trials

How to Search for a Retatrutide Clinical Trial Near Me: Step by Step

There are two reliable starting points: the federal ClinicalTrials.gov registry and Eli Lilly's own trial finder. ClinicalTrials.gov is the most comprehensive; the Lilly finder is the easiest to use and can alert you when a new study opens nearby.

Method 1: ClinicalTrials.gov (Most Comprehensive)

1. Go to ClinicalTrials.gov and click "Find a Study."
2. In the search box, type retatrutide (or the molecule ID, LY3437943).
3. Under "Status," select Recruiting so you see only trials with open enrollment.
4. Under "Location," enter your ZIP code or city and choose a search radius such as 100 miles.
5. Review each result: read the "Brief Summary," then open the "Eligibility" tab.
6. Click "Contacts and Locations" to find the nearest site with open slots.
7. Use the email or phone shown. This reaches the site coordinator, not Lilly's head office.

Method 2: Eli Lilly's Trial Finder

Lilly runs its own location-aware trial finder. It only shows Lilly-sponsored studies, but since retatrutide is exclusively a Lilly compound, that limitation does not matter here. The interface is friendlier for non-researchers, and you can sign up for alerts so Lilly notifies you when a matching trial opens near you. Search "retatrutide," enter your ZIP code, and opt in to alerts.

What to Do If No Trial Is Near You

• Sign up for alerts on the Lilly trial finder so you hear about new sites first.
• Ask your primary care physician or endocrinologist whether they know of local research sites.
• Consider whether traveling is feasible. Some participants drive one to three hours for trials with infrequent visits.
• Contact major academic medical centers and university hospitals in your region and ask if they are running a TRIUMPH study.

What Happens After You Contact a Trial Site?

Knowing the funnel ahead of time means nothing catches you off guard. The exact timeline varies by site, but the sequence is consistent.

1. Pre-screen call or form. The coordinator asks basic eligibility questions by phone or online. This usually takes 10 to 20 minutes.
2. Screening visit. A clinic visit for bloodwork, vitals, BMI measurement, and a medical history review. Plan for a few hours.
3. Eligibility decision. The site reviews your screening results against the inclusion and exclusion criteria, which can take one to four weeks.
4. Informed consent and randomization. If eligible, you review a detailed consent document covering all risks, then a computer assigns you to the drug or placebo arm.
5. Treatment and follow-up. You receive injections and attend periodic visits. Ask the site for the exact schedule, since it differs by trial.

What Clinical Trial Participation Actually Involves

The Placebo Reality

All current TRIUMPH trials are double-blind and placebo-controlled. Depending on the study, somewhere between one in three and one in two participants may receive placebo, and neither you nor your study team knows which arm you are in during the trial. This design is standard for Phase 3 studies and is ethically required to produce reliable results.

Costs and Compensation

The investigational drug is always provided at no cost in a sponsored trial, and you should never be charged to participate. Most sites reimburse for travel and time, but compensation and visit schedules vary by site, so ask the study coordinator about their specific policy before enrolling. Do not treat a clinical trial as an income source; the goal is research participation with medical supervision, not pay.

How Long Will It Take?

TRIUMPH-1 ran for 80 weeks, roughly 18 months. Newer trials may have different durations. Expect a multi-month commitment with periodic clinic visits. Participation is voluntary, and you can withdraw at any time without penalty.

Questions to Ask the Trial Site Coordinator

Copy this checklist and bring it to your pre-screen call. A good coordinator will answer all of these without hesitation.

1. Are you actively accepting new participants right now?
2. What are the exact inclusion and exclusion criteria for this trial?
3. How many clinic visits are required, and at what intervals?
4. Is there a placebo arm, and what is the randomization ratio?
5. What is your reimbursement or compensation policy for visits?
6. Are virtual visits or telephone check-ins available for any appointments?
7. What happens to my treatment after the trial ends, and can I continue on the drug?
8. Who do I contact if I experience side effects between visits?
9. Is there a screening fee, and what does the initial visit involve?
10. If I qualify, what is the earliest I could start?

What Results Have Been Announced So Far?

Knowing what retatrutide has shown so far helps you weigh whether to participate. The figures below come from published and reported trial data.

• Phase 2 (NEJM, 2023, n=338, 48 weeks): up to 24.2% average body-weight loss on the 12mg dose.
• TRIUMPH-4 (NCT05931367, 68 weeks, obesity and knee osteoarthritis): 28.7% average weight loss on 12mg versus 2.1% on placebo.
• TRIUMPH-1 (NCT05929066, n=2,339, 80 weeks, general obesity): 28.3% average weight loss on the 12mg dose.

For the full dose-by-dose breakdown, see our retatrutide Phase 3 results page.

What If You Cannot Qualify or Enroll?

If you cannot join a trial, the only other lawful path is Lilly's expanded access program, which runs before FDA approval "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial" (Reuters via KSL). Patients must be 18 or older with a BMI of 35 or more despite tolerating the highest available dose of weight-management therapy, have two or more serious or life-threatening obesity-related complications, be unable to join an ongoing retatrutide (or comparable) trial, and have discussed all standard treatment options, including bariatric surgery, with their doctor (Lilly Medical; ClinicalTrials.gov NCT07629401). The treating physician applies to the FDA as the sponsor of a patient-specific investigational new drug (IND) application and must obtain institutional review board (IRB) approval. Lilly provides the drug at no cost, and direct-to-patient shipping is not available. It is not something a patient can buy. Outside these two routes, there is no lawful path to retatrutide. The FDA states retatrutide cannot be used in compounding under federal law, so compounding pharmacies cannot lawfully supply it. Research peptide vendors sell it labeled "not for human use," and the FDA has warned companies that illegally sold retatrutide labeled "for research purposes" or "not for human consumption." Neither source provides Lilly's pharmaceutical-grade product or quality controls. Our guide on how to get retatrutide compares the routes people mention, compounded retatrutide explains the compounding ban, and retatrutide vs tirzepatide covers an FDA-approved alternative you can use while you wait.